Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cone Dystrophy Clear all
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

NCT03116113
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIIB112
Biological
Lead sponsor
Biogen
Industry
Eligibility
10 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Not yet recruiting Early Phase 1 Interventional

Topical CBD Scar Outcomes Study

NCT05650697
View directory record Official record
Conditions
Forehead; Wound
Interventions
Group 1 cannabidiol (CBD) with silicone ointment, Group 2 silicone patch
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Color Correcting Lenses on Color Vision Deficiency

NCT05463016
View directory record Official record
Conditions
Color Blindness, Color Vision Defects, Color Blindness, Green, Color Blindness, Red
Interventions
Experimental Group 1: Color Correcting Lenses, Placebo Group 1: Placebo Lenses, Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses, Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses, Color Correcting Lenses in Subjects with Normal Color Vision
Device
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

NCT01530659
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
Interventions
NT-501, Sham
Drug · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CNTF Implants for CNGB3 Achromatopsia

NCT01648452
View directory record Official record
Conditions
Eye Disease, Achromatopsia
Interventions
NT-501 CNTF-releasing implant
Biological
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
View directory record Official record
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT01916109
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Carboplatin, Panitumumab, radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Suspended Early Phase 1 Interventional

PBA Use for Treatment of ATF6-/- Patients

NCT04041232
View directory record Official record
Conditions
ACHROMATOPSIA 7, Achromatopsia
Interventions
PBA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

NCT06395285
View directory record Official record
Conditions
ROSAH
Interventions
DF-003
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

EyeConic: Qualification for Cone-Optogenetics

NCT05294978
View directory record Official record
Conditions
Retinal Dystrophies
Interventions
Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGB3)

NCT03001310
View directory record Official record
Conditions
Achromatopsia
Interventions
AAV - CNGB3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Suspended Phase 2 Interventional

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

NCT04197102
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
CBD Isolate, CBD Broad Spectrum, Placebo oil
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Completed No phase listed Observational

Clinical and Genetic Characterization of Individuals With Achromatopsia

NCT01846052
View directory record Official record
Conditions
Achromatopsia
Interventions
Not listed
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

NCT02935517
View directory record Official record
Conditions
Achromatopsia
Interventions
AGTC-402
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 22, 2026, 2:26 PM EDT
Not listed Phase 2 Interventional

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

NCT01773278
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy, Hearing Loss
Interventions
Antioxidants, Cholesterol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

NCT03920007
View directory record Official record
Conditions
Leber Congenital Amaurosis, LCA, LCA1
Interventions
ATSN-101, ATSN-101 Diluent Solution, Prednisone, Triamcinalone Acetonide, 1% Prednisolone, Trimethoprim/polymyxin B
Drug
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention

NCT04522245
View directory record Official record
Conditions
Obesity, Behavior, Health, Weight Loss
Interventions
Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
Behavioral · Other
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Commack, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Studies in Corticobasal Syndrome

NCT07000851
View directory record Official record
Conditions
Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions
C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
Diagnostic Test
Lead sponsor
Jennifer Whitwell
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Autostereoscopic Dynamic Near Vision Testing

NCT04606355
View directory record Official record
Conditions
Visual Suppression, Amblyopia, Color Vision Defects
Interventions
Visual Acuity, stereopsis, Color vision
Diagnostic Test
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
1 Year to 95 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Not applicable Interventional

Prospective Natural History Study of Retinitis Pigmentosa

NCT04285398
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Ophthalmic examinations, Mobility Test
Other
Lead sponsor
SparingVision
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Color Perception Under LED Red/Green and Green Dominant Light

NCT01927536
View directory record Official record
Conditions
Color Blindness, Acquired
Interventions
White LED Flashlight, Red/Green Green Dominant LED Flashlight
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 66 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2Phase 3 Interventional

Alcohol Use Disorder and Cannabidiol

NCT05613608
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:26 PM EDT